FindTrial
Sign In

Route of administration - Oral

2 trials

Sponsors

NATCO Pharma Limited, Cepham, INC

Conditions

Health Condition 1: null- 1. Patients with metastatic or locally advanced or inoperable solid tumors who have received prior treatment 2. Chronic Myeloid Leukemia patients who are resistant and/or intolerant to Imatinib

Phase 2

A Clinical Study to evaluate the efficacy and safety of NRC-AN-019 in cancer patients failing prior standard therapies
Active, not recruitingCTRI/2013/06/003768
NATCO Pharma LimitedHealth Condition 1: null- 1. Patients with metastatic or locally advanced or inoperable solid tumors who have received prior treatment 2. Chronic Myeloid Leukemia patients who are resistant and/or intolerant to Imatinib
Target: 270Updated: 2023-04-03

Phase 4

A study to test how safe and effective herbal health supplements are for women going through menopause.
RecruitingCTRI/2025/02/079989
Cepham, INC
Target: 120Updated: 2025-03-03